Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Asset Utilization Ratio (2016 - 2024)

Spyre Therapeutics' Asset Utilization Ratio history spans 8 years, with the latest figure at 0.0 for Q1 2024.

  • For Q1 2024, Asset Utilization Ratio fell 91.2% year-over-year to 0.0; the TTM value through Mar 2024 reached 0.0, down 91.2%, while the annual FY2023 figure was 0.0, 83.32% down from the prior year.
  • Asset Utilization Ratio reached 0.0 in Q1 2024 per SYRE's latest filing, down from 0.0 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.3 in Q1 2022 to a low of 0.0 in Q1 2024.
  • Average Asset Utilization Ratio over 4 years is 0.09, with a median of 0.04 recorded in 2022.
  • Peak YoY movement for Asset Utilization Ratio: surged 140.34% in 2022, then plummeted 95.53% in 2023.
  • A 4-year view of Asset Utilization Ratio shows it stood at 0.23 in 2021, then crashed by 87.63% to 0.03 in 2022, then crashed by 88.73% to 0.0 in 2023, then plummeted by 48.59% to 0.0 in 2024.
  • Per Business Quant, the three most recent readings for SYRE's Asset Utilization Ratio are 0.0 (Q1 2024), 0.0 (Q4 2023), and 0.0 (Q3 2023).